Azelis stock weighs Q3 growth against Americas impairment

Azelis reported stronger underlying operating momentum in the third quarter, but a large goodwill impairment in the Americas kept the financial picture mixed. The results were published on October 22, 2026, and the latest detailed review by Ideal Investor highlights both the recovery in demand and the pressure on cash conversion.

Azelis recorded 8.2 percent organic revenue growth in the quarter. Revenue reached 1.122 billion euros, up from 1.015 billion euros a year earlier, while adjusted EBITA rose from 98 million euros to 114 million euros. At constant exchange rates, revenue increased 8.5 percent and adjusted EBITA advanced 14.6 percent, lifting the adjusted EBITA margin to 10.2 percent from 9.7 percent.

Industrial Chemicals Lead The Recovery

Industrial Chemicals was the main growth engine, with quarterly revenue of 451 million euros, up 21.0 percent at constant exchange rates. Life Sciences generated 671 million euros and grew 1.5 percent, although Life Sciences in EMEA declined 3.1 percent to 290 million euros. The differing regional and business-line trends leave execution and mix important for the next reporting periods.

Cash generation was less supportive than the income statement. Quarterly free cash flow fell to 67 million euros from 142 million euros a year earlier. For the first nine months, free cash flow reached 190 million euros, down 35.2 percent, while the conversion rate declined to 54.4 percent from 87.1 percent. Net debt stood at 1.640 billion euros and leverage at 3.46 times EBITDA at the end of September.

Americas Charge Does Not Use Cash

The group recognized a 350 million euro non-cash goodwill impairment linked mainly to acquisitions in the Americas completed between 2021 and 2023. The charge reduced goodwill, equity and reported net income, but had no direct effect on cash flow, working capital or net debt. Goodwill in EMEA and Asia-Pacific was not affected.

Management retained its target for positive organic adjusted EBITA growth in the 2026 financial year. Chief Executive Officer Anna Bertona said earlier recovery signals had been confirmed, while the company also pointed to uneven volume trends and elevated volatility. Azelis does not expect to complete acquisitions in 2026, keeping balance-sheet discipline in focus as leverage remains above the group's target of less than three times EBITDA.

Azelis stock traded at 11.74 euros on Lang & Schwarz at 10:36 CET on Tuesday, November 10, 2026. Investors will likely focus next on cash conversion, leverage reduction and whether the Americas business can rebuild returns under new regional leadership.

The broader Belgian equity backdrop is covered in the BEL20 market overview.

For company developments and investor updates, see More news and analyses on Azelis stock.